Abstracts

NO CSF BIOMARKER EVIDENCE OF PERSISTING CNS INFECTION AFTER SARS-CoV-2 INFECTION

Background: Neurocognitive symptoms are common in acute as well as convalescent (post-acute sequelae of COVID-19 [PASC]) COVID-19, but mechanisms of CNS pathogenesis are unclear. The aim of this study was to investigate cerebrospinal fluid (CSF) biomarker evidence of CNS infection, immune activation and neuronal injury in convalescent compared with acute infection. Methods: We included 68…

CSF & PLASMA SOLUBLE BIOMARKERS IN NEURO-PASC: PRELIMINARY RESULTS FROM COVID MIND

Background: It is unknown whether individuals with neurological post-acute sequelae of COVID-19 (NeuroPASC) display altered levels of neuroimmune activity or neuronal injury. Methods: Participants with new or worsened neurologic symptoms at least 3 months after laboratory-confirmed COVID-19 were enrolled in The COVID Mind Study at Yale. “Never COVID” controls (no history of COVID-19; nucleocapsid (N)…

SOLAR 12-MONTH RESULTS: RANDOMIZED SWITCH TRIAL OF CAB+RPV LA VS ORAL B/FTC/TAF

Background: Cabotegravir (CAB)+rilpivirine (RPV) administered monthly or Q2M is a complete long-acting (LA) regimen for maintaining HIV-1 suppression. We present results from SOLAR, the first randomized comparison of CAB+RPV LA Q2M vs. continued daily oral bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF). Methods: SOLAR (NCT04542070) is a Phase 3b, randomized (2:1), open-label, multicenter, noninferiority (NI) study assessing switching virologically…

EFFECT OF ISLATRAVIR ON TOTAL LYMPHOCYTE AND LYMPHOCYTE SUBSET COUNTS

Background: Islatravir (ISL) is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) being studied for HIV-1 treatment and prevention. Decreases in total lymphocyte counts and CD4+ T-cell counts were observed in several ISL clinical trials. We conducted comprehensive lymphocyte and lymphocyte subset analyses in Phase 2 and Phase 3 clinical trials evaluating oral ISL with doravirine…

HIV CLINICAL, COMORBID, AND SOCIAL DETERMINANTS OF HEALTH ARE LINKED WITH BRAIN AGING

Background: Neuroimaging reveals brain changes linked with HIV infection and neurocognitive disorders. However, group-level differences between persons with HIV (PWH) and persons without HIV (PWoH) conceal substantial within-group heterogeneity in risk factor exposures. PWH experience elevated comorbidities such as cardiovascular disease and socioeconomic deprivation. However, the contribution of such factors to brain aging in PWH…

INCREASED IMMUNE ACTIVATION IN HIV+ MSM ON ART, BUT NOT WHEN COMPARED TO MSM ON PrEP

Background: Persistent systemic and CNS immune activation, as well as signs of neuronal injury, are commonly found in people living with HIV (PLWH) despite suppressive antiretroviral therapy. We have previously shown that HIV-negative persons on PrEP had higher levels of biomarkers for immune activation, blood-brain barrier (BBB) impairment and neuronal injury, compared with volunteers without…